MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

Home・Aandelen Lijst・Quanterix Corp

Quanterix Corp

Open

SectorGezondheidszorg

3.49 6.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.25

Max

3.51

Belangrijke statistieken
By Trading Economics
Inkomsten	10M -23M
Verkoop	3.7M 44M
Winstmarge	-52.712
Werknemers	450
EBITDA	15M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+123.21% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-127M 169M
Vorige openingsprijs	-2.59
Vorige sluitingsprijs	3.49

Nieuwssentiment

By Acuity

50%

154 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

5.34 / 6.015 Steun & Weerstand

Quanterix Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 apr 2026, 23:25 UTC

Belangrijke Nieuwsgebeurtenissen

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 apr 2026, 22:45 UTC

Belangrijke Nieuwsgebeurtenissen

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 apr 2026, 18:03 UTC

Winsten

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 apr 2026, 23:58 UTC

Winsten

Review & Preview: Earnings Time -- Barrons.com

13 apr 2026, 23:49 UTC

Marktinformatie

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 apr 2026, 23:20 UTC

Marktinformatie

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 apr 2026, 23:01 UTC

Winsten

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 apr 2026, 23:01 UTC

Winsten

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 apr 2026, 23:01 UTC

Winsten

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 apr 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 apr 2026, 21:26 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 apr 2026, 21:23 UTC

Winsten

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 apr 2026, 21:16 UTC

Winsten

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

13 apr 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

13 apr 2026, 20:34 UTC

Winsten

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 apr 2026, 20:34 UTC

Winsten

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 apr 2026, 20:34 UTC

Winsten

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 apr 2026, 19:59 UTC

Marktinformatie

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 apr 2026, 19:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 apr 2026, 19:27 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Correction to Precious Metals Market Talk on April 9

13 apr 2026, 19:14 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 apr 2026, 18:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 apr 2026, 18:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 apr 2026, 18:43 UTC

Marktinformatie

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Vergelijking

Prijswijziging

Quanterix Corp Prognose

Koersdoel

By TipRanks

123.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.5 USD 123.21%

Hoogste 8 USD

Laagste 7 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Quanterix Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Quanterix Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.34 / 6.015Steun & Weerstand

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

154 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.